Following the approval in the United States by the Central Institutional Review Board (IRB), the Company has now announced that the first United States recruitment of lupus patients for this pivotal Phase III trial of Lupuzor information will shortly be available on the US National Institute of Health www.ClinicalTrials.gov. The study is entitled -Week, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus S
09 Dec 2015
Patient recruitment for pivotal Phase III Lupuzor trial started in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Patient recruitment for pivotal Phase III Lupuzor trial started in the US
ImmuPharma plc (IMM:LON) | 2.4 0 4.9% | Mkt Cap: 9.79m
- Published:
09 Dec 2015 -
Author:
Capital Access Team -
Pages:
2
Following the approval in the United States by the Central Institutional Review Board (IRB), the Company has now announced that the first United States recruitment of lupus patients for this pivotal Phase III trial of Lupuzor information will shortly be available on the US National Institute of Health www.ClinicalTrials.gov. The study is entitled -Week, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus S